Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Partnership
Glenmark Partners with Pfizer to Launch Abrocitinib in India to Treat Atopic Dermatitis
Details : Glenmark and Pfizer will co-market abrocitinib, a JAK1 inhibitor providing rapid itch relief and sustained control in India as Jabryus and Cibinqo.
Brand Name : Cibinqo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 31, 2024
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Details : CIBINQO (abrocitinib) is an oral inhibitor of Janus kinase 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP).
Brand Name : Cibinqo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 10, 2023
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FDA approval for Cibinqo (Abrocitinib) JAK1 inhibitor, was based on the results of five clinical trials from a large-scale clinical trial program of more than 1,600 patients for the treatment of adults living with refractory, moderate-to-severe atopic de...
Brand Name : Cibinqo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 14, 2022
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The approval of Cibinqo (Abrocitinib) was based on the results of clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adults demonstrated meaningful improvements across measures of symptom relief.
Brand Name : Cibinqo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abrocitinib is oral small molecule that selectively inhibits JAK1. CHMP adopted positive opinion for marketing authorization to treat moderate to severe atopic dermatitis (AD), and CHMP also recommends XELJANZ® (tofacitinib) approval for treatment of a...
Brand Name : Cibinqo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Pfizer Inc today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO® (abrocitinib).
Brand Name : Cibinqo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 09, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abrocitinib 200mg was administered by once-daily oral tablet and dupilumab was administered by subcutaneous injection every other week following a 600mg induction dose.
Brand Name : PF-04965842
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and Xeljanz® Filings
Details : Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of atopic dermatitis.
Brand Name : PF-04965842
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 21, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Patients were randomized into one of three arms: 200mg, 100mg, or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing flaring, compared to those randomized to placebo.
Brand Name : PF-04965842
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 11, 2020
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib
Details : Filings based on robust abrocitinib clinical trial data demonstrating significant symptom improvement versus placebo as well as a consistent safety profile.
Brand Name : PF-04965842
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2020
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?